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Cisplatin  (CP)  is  a potent  anti-cancer  drug  widely  used  against  solid  tumors.  However,  it exhibits  pro-
nounced  adverse  effects  including  hepatotoxicity.  Several  strategies  were  attempted  to  prevent  CP
hepatotoxicity  but were  not  found  suitable  for therapeutic  application.  Nigella  sativa  has  been  shown  to
prevent/reduce  the  progression  of certain  type of  cardiovascular,  kidney  and  liver  diseases.  Present  study
investigates  whether  N.  sativa  oil  (NSO)  can  prevent  CP  induced  hepatotoxic  effects.  Rats  were  divided
into  four  groups  viz.  control,  CP,  NSO  and  CPNSO.  Animals  in  CPNSO  and  NSO  group  were  administered
NSO  (2  ml/kg  bwt,  orally)  with  or without  single  hepatotoxic  dose of  CP (6 mg/kg  bwt,  i.p.)  respectively.
CP  hepatotoxicity  was  recorded  by increased  serum  ALT  and  AST  activities.  CP  treatment  caused  oxi-
dant/antioxidant  imbalances  as reﬂected  by  increased  lipid peroxidation  and  decreased  enzymatic  and
non-enzymatic  antioxidants.  Furthermore,  the activities  of various  carbohydrate  metabolism  and  mem-
brane enzymes  were  altered  by CP treatment.  In  contrast,  NSO  administration  to CP  treated  rats,  markedly
ameliorated  the  CP  elicited  deleterious  alterations  in liver.  Histopathological  observations  showed  exten-
sive liver  damage  in CP treated  animals  while  greatly  reduced  tissue  injury  in  CPNSO  group.  In conclusion,
NSO  appears  to protect  CP  induced  hepatotoxicity  by improving  energy  metabolism  and strengthening
antioxidant  defense  mechanism.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. IntroductionCisplatin (cis-diamminedichloroplatinum II, CP) is one of the
ost effective chemotherapeutic agent used in the treatment of
ariety of human malignancies including those of bladder, head,
Abbreviations: ACPase, acid phosphatase; ALP, alkaline phosphatise; ALT, ala-
ine  aminotransferase; AST, aspartate aminotransferases; BUN, blood urea nitrogen;
BM, brush border membrane; BBMV, BBM vesicles; Scr, serum creatinine; CAT,
atalase; CP, cisplatin; Chl, cholesterol; FBPase, fructose 1,6; G6Pase, glucose 6-
hosphatase; G6PDH, glucose 6-phosphate dehydrogenase; GGTase, -glutamyl
ransferase; Glc, glucose; GR, glutathione reductase; GSH, glutathione; GSHPx,
lutathione peroxidise; GST, glutathione S-transferase; HK, hexokinase; H2O2,
ydrogen peroxide; LAP, leucine aminopeptidase; LDH, lactate dehydrogenase; LPO,
ipid peroxidation; MDA, malondialdehyde; MDH, malate dehydrogenase; ME,  malic
nzyme; m,  micrometer; NADPH, nicotinamide adenine dinucleotide phosphate
educed; NADP, nicotinamide adenine dinucleotide phosphate; NSO, Nigella sativa
il; Pi, inorganic phosphate; PLs, phospholipids; PUFA, polyunsaturated fatty acids;
OS,  reactive oxygen species; SH, sulfhydryl; SOD, superoxide dismutase; TCA, tri-
arboxylic acid; TR, thioredoxin reductase.
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neck, testis and ovary [1,2]. However, the use of high dose of CP is
difﬁcult in clinical practice due to the associated side effects such as
nephrotoxicity, neurotoxicity and ototoxicity. Recent studies sug-
gest that hepatotoxicity is also a major dose limiting side effect in
CP based chemotherapy [3,4]. High dose protocol of CP chemother-
apy, therefore, necessitates the investigation of ways for prevention
of dose limiting side effects that inhibit CP administration at tumo-
ricidal doses. Until now, various methods to prevent or reduce the
side effects of CP, such as synthetic antioxidants and chemopro-
tective agents, have been tested but effective method for clinical
application has not yet been established [5,6].
CP induced toxicity is reported to be mediated by increased pro-
duction of reactive oxygen species (ROS) and free radicals [3,7].
These ROS could interfere with the antioxidant defense system and
can cause extensive tissue damage and cell dysfunction by reacting
with macromolecules like proteins, membrane lipids and nucleic
acids [7–10]. Several studies suggest that oxidative stress plays
an important role in CP induced hepatotoxicity [11,12]. Naturally
occurring dietary antioxidants therefore have excellent scope to
protect against CP hepatotoxicity. In consequence, the search for
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ffective, naturally occurring dietary substances with antioxidant
ctivity, has been intensiﬁed in recent years. Plants such as Nigella
ativa (NS) provide such a dietary source of biologically active com-
onents/phytochemicals which exhibit wide spectrum of biological
roperties such as antioxidant, anti-diabetic, anti-inﬂammatory,
ephroprotective and hepatoprotective properties [13,14]. NS oil
NSO) contains ﬁxed oil (30%) and volatile oil (0.5%), proteins, alka-
oids and saponins. Thymoquinone, the principal active ingredient
f NS volatile oil, possesses antioxidant potential to scavenge free
adicals and to protect the cell against oxidative damage [15–17]. In
ddition, NSO is an important source of polyunsaturated fatty acids
PUFA) that contains omega ()-3 PUFA and -6 PUFA in the recom-
ended optimal dietary intake ratio of 1:4 [18,19]. Consumption
f -3 and -6 essential fatty acid in the right proportion has been
ound to suppress the pathogenesis of many diseases [20,21].
Since ancient times, NS seed/oil consumption has been shown
o exhibit a multitude of beneﬁcial health effects under normal
s well as in various pathological conditions [14]. NSO has been
hown to downregulate CCl4 induced nitric oxide (NO) synthase
RNA and NO production in liver [22]. Thymoquinone, the major
ioactive component of NSO, has been reported to improve plasma
nd liver antioxidant capacity and to enhance the expression of
iver antioxidant genes in hypocholestrolemic rats [23]. Studies
ave shown that NSO/thymoquinone administration ameliorates
P induced nephrotoxic effects [24,25]. Thymoquinone was  also
ound to potentiate/enhance the anti-tumor activity of CP against
hrlich ascites carcinoma (EAC) [24]. NSO has been demonstrated
o attenuate cyclosporine A and gentamicin induced renal dysfunc-
ion in experimental rats [26,27]. However, the protective potential
f NSO against CP induced hepatotoxicity remains uninvestigated.
Considering the potential clinical use of CP and numerous
ealth beneﬁts of NSO, we hypothesized that owing to its inher-
nt biochemical and antioxidant properties, NSO would prevent CP
nduced hepatotoxicity that would lead to improved metabolism
nd antioxidant defense mechanism of the liver.
. Material and methods
.1. Chemicals and drugs
N. sativa oil was supplemented from Mohammedia Products,
ed Hills, Nampally, Hyderabad, India. Cisplatin was obtained from
igma–Aldrich Chemical Corp., St. Louis, MO,  USA. All other chemi-
als used were of analytical grade and were purchased either from
igma Chemical Corp., or SRL (Mumbai, India).
.2. Diet
A nutritionally adequate laboratory pellet diet was  obtained
rom Aashirwaad Industries, Chandigarh (1544, Sector 38-B,
handigarh, India).
.3. Experimental design
The animal experiments were conducted according to the guide-
ines of Committee for purpose of Control and Supervision of
xperiments on Animals (CPCSEA), Ministry of Environment and
orests, Government of India. Adult male Wistar rats (6 rats/group)
eighing between 150 and 200 gm were used in the following
xperimental protocol. Rats were acclimatized to the animal facil-
ty for a week on a standard rat laboratory pellet diet and allowed
ater ad libitum under controlled conditions of 25 ± 2◦ C tempera-ure, 50 ± 15% relative humidity and normal photoperiod (12 h dark
nd light). Four groups of rats entered the study after acclima-
ization; Control (C), CP treated (CP), N. sativa oil treated (NSO)
nd N. sativa oil + CP treated (CPNSO). Rats in the group CPNSOeports 3 (2016) 328–335 329
were administered NSO (2 ml/kg bwt, orally) for 14 days prior to
and 4 days following CP treatment. However, rats in NSO group
were administered NSO alone without CP treatment. CP solution
(2 mg/ml) was  freshly prepared in 0.9% normal saline by continuous
stirring at room temperature for 10 min. A single intraperitoneal
injection of CP (6 mg/kg bwt.) was administered to the animals in
CP and CPNSO groups, while animals in the control and NSO group
received an equivalent amount of normal saline. Body weight of
rats was recorded at the start and completion of the experimental
protocol. Blood was collected from fasted rats on 5th day after CP
administration under light ether anesthesia. Liver was  removed and
processed for histopathology and the preparation of homogenate
as described below.
2.4. Serum parameters
Blood samples were centrifuged at 2000 × g for 10 min  and
sera were separated. Serum samples were deproteinated with 3%
trichloroacetic acid in a ratio of 1:3, left for 10 min  and then cen-
trifuged at 2000 × g for 10 min. The precipitate obtained was used
to quantitate total phospholipids (PLs). Cholesterol (Chl) levels was
determined directly in serum samples by method of Zlatkis et al.
[28]. Alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) activities were determined in serum by Reitman and
Frankel method using kit from span diagnostics.
2.5. Preparation of homogenates
Liver was homogenized in 0.1 M Tris–HCl buffer (pH 7.5) by a
glass–teﬂon homogenizer (Thomas PA, USA) by passing 5 pulses; at
4◦ C to make a 10% (w/v) homogenate. The homogenate was  then
subjected to high-speed Ultra-Turrex Kunkel homogenizer (Type
T-25, Janke & Kunkel GMBH & Co., KG. Staufen) for 3 pulses of
30 s each with an interval of 30 s between each stroke. One  part
of the homogenate was saved at −20◦ C for estimation of GSH,
total-SH and lipid peroxidation while other part was  centrifuged at
2000 rpm for 10 min at 4◦ C in high-speed Remi centrifuge (Remi
motors, Mumbai, India) to remove the cell debris. The super-
natant was  saved in aliquots and stored at −20◦ C for analyses of
membrane, carbohydrate metabolism and free radical scavenging
enzymes.
2.6. Assay of carbohydrate metabolism enzymes
The activities of the enzymes involving oxidation of NADH
or reduction of NADP were determined spectrophotometrically
on UV-1700 (Pharma Spec, Shimadzu Corp., Japan) ﬁxed for
340 nm using 3 ml  of assay buffer in a 1-cm cuvette at room
temperature (28–30 ◦C). The enzyme activities of lactate dehy-
drogenase (LDH), malate dehydrogenase (MDH), malic enzyme
(ME), glucose-6-phosphate dehydrogenase (G6PDH), glucose-6-
phosphatase (G6Pase) and fructose-1, 6-bisphosphatase (FBPase)
were assayed as described by Khundmiri et al. [29]. Hexokinase
(HK) was  estimated by the method of Crane and Sols [30] and the
remaining glucose was  measured by method of Nelson [31].
2.7. Assay of membrane enzymes and lysosomal marker enzyme
The activities of membrane marker enzymes viz. alkaline phos-
phatase (ALP), -glutamyl transferase (GGTase), leucine amino
peptidase (LAP), and lysosomal marker enzyme viz. acid phos-
phatase (ACPase) were determined as described by Farooq et al.
[32].
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Table 1
Effect of NSO on serum parameters with/without CP treatment.
Enzymes/parametersGroups ALT (IU/L) AST (IU/L) Cholesterol (mg/dl) Phospholipid (mg/dl)
Control 45.65 ± 2.55 26.65 ± 0.25 86.85 ± 2.64 209.68 ± 7.56
CP  74.12 ± 2.22* (+62%) 41.60 ± 0.60* (+56%) 112.64 ± 3.06* (+30%) 260.15 ± 1.78* (+24%)
NSO  34.65 ± 2.08* (−24%) 27.25 ± 1.35 (+2%) 61.59 ± 1.68* (−29%) 196.97 ± 3.1 (−6%)
CPNSO 35.35 ± 3.05** (-22%) 30.41 ± 1.36**(+14%) 81.44 ± 0.81** (-6%) 210.48 ± 3.57** (+0.38%)
CP: cisplatin treated; NSO: Nigella sativa oil administered; CPNSO: Nigella sativa oil administered + cisplatin treated; ALT: alanine aminotransferases; AST: aspartate amino-
transferases. Results are mean ± SEM for three different experiments. Values in parenthesis represent percent change from control.
* Signiﬁcantly different from control.
** Signiﬁcantly different from CP at p < 0.05 by one way ANOVA.
Table 2
Effect of NSO on membrane and lysosomal enzymes in liver homogenate with/without CP treatment.
EnzymeGroups ALP (mol/mg protein/h) GGTase (mol/mg protein/h) LAP (mol/mg protein/h) ACPase (mol/mg protein/h)
Control 8.60 ± 0.212 1.17 ± 0.087 0.76 ± 0.046 2.75 ± 0.214
CP  5.77 ± 0.125* (−32%) 0.76 ± 0.091* (−35%) 0.38 ± 0.017* (−50%) 4.48 ± 0.240* (+62%)
NSO  9.20 ± 0.481 (+6%) 1.22 ± 0.044 (+4%) 0.91 ± 0.032* (+19%) 2.17 ± 0.160* (−21%)
CPNSO 8.39 ± 0.133** (−2%) 1.09 ± 0.043** (−6%) 0.71 ± 0.032** (−6%) 3.22 ± 0.111 (+17%)
CP: cisplatin treated; NSO: Nigella sativa oil administered; CPNSO: Nigella sativa oil administered + cisplatin treated; ALP: alkaline phosphatase; GGTase: —glutamyl trans-
ferase;  LAP: leucine amonipeptidase; ACPase: acid phosphatase. Results (speciﬁc activity expressed as moles/mg protein/h) are mean ± SEM for three different experiments.
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* Signiﬁcantly different from control.
** Signiﬁcantly different from CP at p < 0.05 by one way ANOVA.
.8. Assay of enzymes involved in free radical scavenging
Superoxide dismutase (SOD) was assayed by the method of
arklund and Marklund [33]. Catalase (CAT) and glutathione per-
xidase (GSH-Px) activities were determined by the method of Giri
t al. [34] and Flohe and Gunzler [35], respectively. The activi-
ies of thioredoxin reductase (TR) and glutathione-S-transferase
GST) were determined using 5,5′-dithiobisnitrobenzoic acid and
-chloro-2-4-dinitrobenzene as substrates, respectively [36,37].
lutathione reductase (GR) was assayed from the oxidation of
ADPH to NADP+ in presence of oxidized glutathione [38].
.9. Thiobarbituric acid reactive substances (TBARS), total −SH
roup and GSH estimation
TBARS (products of LPO) were measured as malondialde-
yde (MDA) equivalents as described by Ohkawa et al. [39].
otal-SH and GSH were determined after reaction with 5,5′-
ithiobisnitrobenzoic acid by the method of Sedlak and Lindsay
40] and Jollow et al. [41], respectively.
.10. Histopathology
Liver was cut into pieces and kept in Karnovsky’s ﬁxative for
ne week (Immersion ﬁxation). Small pieces of tissue samples were
rocessed for parafﬁn embedding. Sections of 7 m thickness were
ut and stained with haematoxylin and eosin. Light microscopic
bservations were made under trinocular microscope (Olympus
X-40, Japan). Interesting ﬁndings were recorded at the initial mag-
iﬁcation of ×400.
.11. Statistical analysis
All data are expressed as mean ± SEM for at least 3 differ-
nt experiments. Statistical evaluation was conducted by one-way
NOVA using origin 6.1 software followed by post hoc test
Student–Newman–Keuls and Dunnets multiple comparison test).
 probability level of p < 0.05 was selected as indicator of statisti-
al signiﬁcance. Most of the changes between various groups were
ompared with control values for better understanding and clarity.However, speciﬁc differences and statistical signiﬁcance between
other groups were evaluated separately, e.g., CP vs. CPNSO.
3. Results
The present work was undertaken to study the detailed mech-
anism of CP-induced deleterious effects on liver and possible
protection by N. sativa oil (NSO). The effect of CP alone and in combi-
nation with NSO was  determined on various serum parameters and
membrane marker enzymes, enzymes of carbohydrate metabolism
and oxidative stress parameters in rat liver.
3.1. Effect of NSO on CP induced alterations in serum parameters
Hepatotoxicity induced by CP was characterized by signiﬁcant
increase in serum transaminases, ALT and AST. The administration
of CP caused signiﬁcant increase in ALT (+62%), AST (+56%), Chl
(+30%) and PLs (+24%) (Table 1). NSO administration prior to and
following CP treatment, resulted in signiﬁcant reversal of various
CP-elicited deleterious effects on serum parameters. CP-induced
increase in ALT, AST, PLs, and Chl were prevented by NSO admin-
istration. However, NSO administration alone caused signiﬁcant
decrease in ALT and Chl.
3.2. Effect of NSO on CP induced alterations in membrane
enzymes and biomarker enzymes of lysosomes
To evaluate the structural integrity of certain organelles e.g.,
plasma membrane and lysosomes, the effect of CP alone and in
combination with NSO was  determined on membrane and lyso-
somal marker enzymes (Table 2). CP treatment caused signiﬁcant
decrease in the speciﬁc activities of membrane enzymes viz. ALP
(−32%), GGTase (−35%) and LAP (−50%) in liver homogenate.
Administration of NSO to CP treated rats prevented CP induced
decline in membrane enzyme activities. However, the activity of
ACPase, a lysosomal enzyme, was  increased (+62%) by CP treatment
in liver homogenate. However, NSO administration prior to and
following CP treatment, improved ACPase activity insigniﬁcantly
compared to CP group.
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3.3. Effect of NSO on CP induced alterations in carbohydrate
metabolism
The effect of CP and NSO alone and their combination (CPNSO)
was determined on the activities of various enzymes of carbohy-
drate metabolism. As shown in Table 3, CP treatment signiﬁcantly
enhanced the activity of LDH (+37%) and decreased the activity of
MDH  (−61%) while activity of HK was  altered insigniﬁcantly by
CP treatment in the liver. In contrast, when CP was  administered
to NSO consuming rats, CP-induced decline in MDH  activity and
enhancement in LDH and HK activities was  prevented (Table 3).
CP treatment was  found to cause a marked reduction in gluco-
neogenic enzymes viz. G6Pase and FBPase activities in the liver.
In contrast, NSO administration prior to and following CP treat-
ment, reduced CP induced decline in G6Pase and FBPase activities.
The activities of G6PDH and ME,  that provide NADPH needed in
various anabolic reactions, were also determined. CP treatment sig-
niﬁcantly decreased G6PDH activity (−64%) while activity of ME
was profoundly increased (+95%) in the liver (Table 3). Administra-
tion of NSO alone to the rats did not cause signiﬁcant alterations
in the activities of carbohydrate metabolism enzymes except for
the signiﬁcant reduction of G6Pase. However, CP treatment to NSO
administered rats signiﬁcantly reduced the CP induced alterations
in the activities of G6PDH and ME.
3.4. Effect of NSO on CP induced alterations in antioxidant
defense parameters
The effect of CP-induced toxicity was  assessed on the antioxi-
dant system and MDA. CP treatment resulted in profound increase
in the production of malondialdehyde (MDA), an end-product of
lipid peroxidation. Total-SH and GSH were found to decrease signif-
icantly in CP treated rats (Table 4). CP treatment caused signiﬁcant
decline in the activities of SOD (−30%), CAT (−43%), GSH-Px (−35%),
TR (−62%), GR (−44%) and GST (−41%) (Table 5). Administration of
NSO alone had no signiﬁcant effect on the activities of antioxidant
enzymes. However, administration of NSO to CP treated rats sig-
niﬁcantly prevented CP induced increase in MDA  and decrease in
GSH in the liver homogenate. NSO treatment signiﬁcantly reduced
the CP induced decrease in the activities of antioxidant enzymes
viz. SOD, CAT, GSH-Px, GR and GST, while the activity of TR was not
effected signiﬁcantly by NSO administration. In general, the present
results demonstrate marked prevention of CP induced alterations
in oxidative stress parameters by NSO administration.
3.5. Histopathological observations
Histopathological observations (Fig. 1) are suggestive of obvious
and extensive damage to the liver by CP treatment. CP treatment
(Fig. 1B) lead to loss of normal histoarchitecture, disorganised hep-
atic cords, necrosis of hepatocytes and congested sinusoids. NSO
treatment does not show such kind of toxic effects (Fig. 1C). The
combination group (CPNSO) shows promising protective potential
of NSO against the damaging effects of CP on liver (Fig. 1D).
4. Discussion
Liver is an important organ to be considered when the effect
of CP are investigated, since it plays a central role in the body’s
metabolism of drugs and other xenobiotics. Liver is known to accu-
mulate signiﬁcant amount of CP and therefore, high dose protocol
of CP chemotherapy causes hepatotoxicity. Although CP induced
nephrotoxicity has been very well studied in both clinical and ani-
mal  researches, hepatotoxicity has been rarely characterized and is
less studied [3,42,43]. Several studies have demonstrated that CP
332 Z. Farooqui et al. / Toxicology Reports 3 (2016) 328–335
Table 4
Effect of NSO on non-enzymatic antioxidant parameters in liver homogenate with/without CP treatment.
ParametersGroups Lipid peroxidation (nmol/g tissue) Total SH (mol/g tissue) GSH (mol/g tissue)
Control 258.72 ± 2.00 19.21 ± 0.744 0.98 ± 0.035
CP  335.46 ± 5.31* (+229%) 15.55 ± 0.824* (−19%) 0.55 ± 0.039* (−44%)
NSO  210.97 ± 8.03* (−18%) 20.88 ± 0.270 (+8%) 0.87 ± 0.035 (−11%)
CP  NSO 274.03 ± 3.28** (+5%) 17.94 ± 0.603 (−6%) 0.79 ± 0.054** (−19%)
CP: cisplatin treated; NSO: Nigella sativa oil administered; CPNSO: Nigella sativa oil administered + cisplatin treated; GSH: glutathione. Results are mean ± SEM for three
different  experiments. Values in parenthesis represent percent change from control.
* Signiﬁcantly different from control.
** Signiﬁcantly different from CP at p < 0.05 by one way ANOVA.
Fig. 1. Histopathology of rat liver showing hepatocytes ( ) and sinusoids ( ) in control (A) with normal histoarchitecture of hepatocytes and intact hepatic cord whereas
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rn  CP treated group (B) disorganised hepatic cords, necrosis of hepatocytes and c
onditions of both, hepatocytes and sinusoids very similar to control. CPNSO group (
inusoids appear moderately congested as compared to control. H & E stain, initial 
nduces pronounced histopathological abnormalities viz. inﬂam-
atory inﬁltration, dissolution of hepatic cord, dilated sinusoids
nd extensive disorganisation of hepatocytes [44,45]. The toxic
ffects of CP are attributed to its ability to induce formation of ROS
hat lead to oxidative stress, which is one of the major pathogenic
echanism involved in CP induced damage to kidney and liver
8,10–12].
In the past few years, much interest has been focussed on the
ole of naturally occurring dietary substances for their ability to
onfer health and physiological beneﬁts. N. sativa has been revered
hroughout history for its medicinal properties. N. sativa seed and
ts oil have been shown to provide potential therapeutic beneﬁts in
 variety of diseases [14,16]. Several studies have shown that NSO
rotects against drug and chemical induced toxicities [27,46]. How-
ver, the ameliorative potential of NSO in CP induced hepatotoxicity
as not yet been explored.
The present investigation was carried out to study the possible
ole of NSO in preventing CP induced deleterious effects in rat liver.
ingle intraperitoneal injection of CP caused marked alterations
n serum parameters. Results (Table 1) show that CP administra-
ion caused hepatotoxicity, as indicated by elevated serum levels
f transaminases viz. ALT and AST. Serum cholesterol and PLs were
lso increased signiﬁcantly in CP treated rats. However, NSO admin-
stration prior to and following CP treatment, resulted in signiﬁcant
owering of CP elicited increase in serum transaminases. Further-
ore, NSO consumption either alone or in combination with CP
reatment, caused signiﬁcant decline in serum cholesterol and that
ight be attributed to the hypocholesterolemic effect of NSO as
eported previously [47].ted sinusoids were observed. NSO administered group (C) shows well preserved
ws fairly intact histoarchitecture, hepatic cords and no obvious necrosis. However,
ﬁcation ×400 scale bar = 50 m.
The effect of CP and NSO alone and in combination, on the hep-
atocyte membrane, was  assessed by the status of its biomarker
enzymes viz. ALP, GGTase and LAP. CP treatment caused signiﬁ-
cant decline in the activities of ALP, GGTase and LAP in the liver
homogenate (Table 2). The decrease in the membrane enzyme
activities could be due to the oxidative modiﬁcation and con-
sequent inactivation of enzymes by CP generated free radicals
and ROS. Initiation of self-propagating LPO reactions due to inter-
action of CP generated ROS with membrane PUFA, could have
impaired membrane structure and functions, resulting in the loss
of membrane enzymes. In contrast, NSO administration alone,
caused signiﬁcant increase in the activities of membrane enzymes
while, NSO administration to CP treated rats prevented/retarded
CP-induced decrease in membrane enzyme activities in the
liver. Reduction in LPO and oxidative modiﬁcation of membrane
enzymes by NSO, owing to the intrinsic antioxidant and free radi-
cal scavenging properties of its bioactive constituents might have
caused the observed increase of membrane enzyme activities in CP-
treated NSO-fed rats [23,48]. NSO, being a good source of essential
fatty acids, might have replaced the PUFA components of cellu-
lar membranes that had been attacked by oxygen free radicals
[49,50], thereby accelerating the repair process. Hence, NSO seems
to prevent the membrane perturbing effects of CP, by lessening the
damage caused and/or by accelerating the repair or regeneration
process, resulting in improved membrane integrity. The restora-
tion of membrane integrity might have caused decreased leakage
of enzymes from hepatocytes into the blood, as evidenced by the
observed decline in serum ALT and AST activities in CPNSO group.
In agreement to earlier studies, CP treatment caused signiﬁcant
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increase in ACPase activity in liver [51]. Morphologically, increase
in the size and number of lysosomes after CP treatment has been
reported previously [52]. However, NSO administration prior to
and following CP treatment, ameliorated the CP induced increase
in ACPase activity.
Since energy depletion of cells perpetuated by disruption of
metabolic pathways is a crucial factor in CP induced toxicity,
hence it is imperative to evaluate the possible amelioration of CP
induced alterations in hepatic metabolism by oral NSO administra-
tion. To assess the effect of CP alone and in combination with NSO,
on hepatic metabolic functions, the activities of various enzymes
involved in glycolysis, tricarboxylic acid (TCA) cycle, gluconeo-
genesis and hexose monophosphate-shunt (HMP) pathway were
examined in liver homogenates prepared from animals in differ-
ent experimental groups (Table 3). The enzyme activities were
differentially altered by CP treatment and/or by NSO consump-
tion. CP administration led to signiﬁcant increase in the activities
of HK and LDH (glycolysis) but decrease in the activity of MDH
(TCA cycle). Although the actual rates of glycolysis and other path-
ways were not determined, however the increased activity of LDH
along with simultaneously reduced activity of TCA cycle enzyme,
suggest a shift in energy production from aerobic to anaerobic
mode, apparently due to CP induced mitochondrial dysfunction
[53,54]. The activities of FBPase and G6Pase (gluconeogenesis) also
declined signiﬁcantly in CP treated rats. The decreased activities
of gluconeogenic enzymes might be a consequence of decreased
MDH  activity. Thus, in CP treated rats the reduced production of
oxaloacetate from malate due to decreased MDH  activity, seems to
affect both TCA cycle and gluconeogenesis. The NADPH producing
enzymes viz. G6PDH and ME  were differentially altered by CP treat-
ment. The oxidative conversion of glucose or glucose 6 phosphate
to 6 phosphogluconate by G6PDH via HMP  shunt pathway, was
lowered in CP treated rats and that might be a consequence of CP
induced damage to mitochondria [54]. The decreased generation of
NAPDH, essential for reductive biosynthetic processes, due to low-
ered G6PDH activity, seems to be compensated by the increased
activity of NADP malic enzyme. However, NSO consumption by CP
treated rats, resulted in an overall improvement of carbohydrate
metabolism as evident by higher activities of MDH, G6PDH and
gluconeogenic enzymes in CPNSO in comparison to CP group. These
biochemical ﬁndings were further conﬁrmed by histopathological
studies that showed loss of normal histoarchitecture, disorganised
hepatic cords, congested sinusoids and necrosis of hepatocytes in
the liver of CP treated rats (Fig. 1B). However, administration of NSO
to CP treated rats, prevented CP induced histopathological alter-
ations and maintained the architecture of liver almost similar to
that of control (Fig. 1D).
Various studies have revealed that CP exerts its toxic effect by
generation of ROS and free radicals [7,55,56]. The role of ROS in
CP toxicity is strengthened by the fact that many free radical scav-
engers, such as green tea, vitamin E and ascorbic acid were able
to provide marked protection against in vivo CP toxicities [56,57].
In agreement with the previous studies, CP signiﬁcantly depleted
GSH and protein thiols in liver and enhanced LPO, as evidenced
by increased malondialdehyde levels, suggesting the induction of
oxidative stress [42,58]. However, oxidative stress could be a conse-
quence of increased ROS generation and/or decreased antioxidant
defense. SOD and CAT provide major cellular defense against ROS
and together they convert superoxide radicals ﬁrst to H2O2 and
then to molecular oxygen and water. Another enzyme viz. GSH-Px
uses thiol reducing power of GSH to reduce oxidised lipid and pro-
tein targets of ROS. Activities of SOD, CAT and GSH-Px declined
signiﬁcantly in hepatic tissue of CP treated rats (Table 5). The
observed decrease in the activity of SOD, CAT and GSH-Px might
be due to the inhibition of functional SH group of the enzymes by
CP, as suggested earlier [59]. Reduced activities of these antioxidant
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nzymes would have caused decreased scavenging of ROS, thus
ncreasing the susceptibility of hepatic tissue to oxidative damage.
n contrast, marked increase in the activities was seen when rats
ere orally administered NSO. Furthermore, NSO administration
o CP treated rats, prevented CP induced augmentation of LPO and
uppression of SOD, CAT and GSH-Px activities. This is in agree-
ent with previously reported studies that have shown NSO or
ts constituents viz. p-cymene, carvacrol and in particular thymo-
uinone to protect against oxidative stress related pathologies by
irectly scavenging free radicals and/or by enhancing the activities
f antioxidant enzymes [16,22,60]. GSH, plays a major role in pro-
ecting cells against oxidative stress. CP is reported to alter cellular
SH levels either by directly binding with it or by oxidizing GSH
ia CP induced free radical generation [58,59,61]. Activity of GR,
he enzyme responsible for recycling of GSH from oxidized form
GSSG) to the reduced form (GSH), was signiﬁcantly decreased by
P treatment (Table 5). This would have further lowered the levels
f GSH which is necessary cofactor for the detoxiﬁcation of H2O2
nd hyderoperoxides. TR, a part of the thioredoxin system, is the
ajor cellular disulﬁde reductase that also functions in defense
gainst oxidative stress [62].
Activity of TR was also found to decline signiﬁcantly in CP
reated rats (Table 5). Reduced G6PDH activity in CP treated
roup could have resulted in reduced activities of GR and TR,
s both the enzymes essentially require NADPH for their activ-
ties. Depressed activities of GR and TR along with suppressed
OD, CAT and GSH-Px activities indicate that CP has an inhibitory
ffect on the endogenous antioxidant defense system and that con-
rms the involvement of ROS in CP hepatotoxicity as reported
arlier [3,11]. However, oral NSO administration attenuated the CP
nduced decline in GSH levels and antioxidant enzyme activities,
hus empowering the endogenous antioxidant defense against CP
nduced oxidative damage to liver.
. Conclusions
CP treatment elicited deleterious hepatotoxic effects by causing
ajor damage to mitochondria, lysosomes and plasma membrane
s reﬂected by signiﬁcant decrease in the activities of speciﬁc
arker enzymes. CP treatment seems to increase cellular energy
ependence on anaerobic glycolysis and that might be due to the CP
nduced mitochondrial damage. CP also inhibited the endogenous
hysiological antioxidant defense system and induced oxidative
tress which at least in part may  have mediated its hepatotoxic
ffects. In contrast, NSO seems to accelerate repair/regeneration of
njured organelles viz. mitochondria and cell membrane as evident
y increased activities of TCA cycle and membrane enzymes and as
bserved by histopathological examination. Most importantly, by
mproving the endogenous antioxidant status and metabolic activ-
ty, NSO protects the liver against CP generated free radical attack.
he study put forth a good basis for NSO as new adjuvant of CP, to
brogate the hepatotoxicity induced upon cancer chemotherapy.
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